The latest from BioStock
» Saniona provided an update regarding tesofensine
» BiBBInstruments CEO: "Distributors are contacting us"
» Alzinova CEO: “We look forward to analyzing and communicating the results”
» Elicera CEO: “One of the biggest milestones in our history”
» Cyxone trading halted and received payment demands
Read the newsletter for v.44 here.
Do not miss BioStock Life Science Summit 2024 November 20-21 at Medicon Village in Lund!
The latest news
A patent for laquinimod in eye diseases will be granted in the United States. Read more.
Preclinical data for Cereno Scientifics new IP receptor agonists, which were presented at ESC 2024, are now published in the European Heart Journal. Read more.
BibbInstruments has initiated a collaboration with Swedish contract manufacturer Cenova. Read more.
CLS receives additional guarantee commitments of approximately SEK 5,8 million for warrants of series TO 7. Read more.
Phase Holographic decides on a fully secured rights issue of shares of approximately SEK 64,3 million. Read more.
Expression and Evaxion announces positive preclinical data for the cytomegalovirus (CMV) vaccine program ES2B-I002. Read more.
SciBase initiates collaboration to predict atopic dermatitis in infants. Read more.
Curasight announces international patent application for uTREAT to broaden IP protection. Read more.
All patients have undergone AcuCorts phase IV study ZEQ001. Read more.
Bio-Works Technologies announces that the letter of intent (LOI) previously received has been increased, with a new expected order value of SEK 11,9 million. Read more.
Members of Lumitos The board of directors and management intend to exercise warrants of series TO6. Read more.
Dignity announces that the University Hospital Schleswig-Holstein in Kiel, Germany selects DigniCap. Read more.
Peptonic Medical is winding down its Israeli subsidiary. Read more.
Presentation of board candidate to PolarCools board. Read more.
Bio Vitos Pharma informs shareholders of Homecheck Holding. Read more.
Doctor.se and Zenicor signs an agreement for early diagnosis of arrhythmia patients. Read more.
Jan-Mark Edewaard has been appointed as the new CEO of ODI Pharma. Read more.
Quia Pharma provides an update on the development work on a patch for obesity. Read more.
Circio Holding informs about requested conversion of convertible bonds. Read more.
A Declaration of Conformity has been signed for Observe Medical UnoMeter SafeIT Plus, and an industry partner have committed to an equity investment. Read more.
Pila Pharma announces progression and co-sponsorship of preclinical research collaboration in cardiovascular diseases. Read more.
FluoGuide issues warrants to board members, CMO and CFO. Read more.
Last day for trading in warrants of series TO 7 in Wntresearch is tomorrow, November 14th. Read more.
Reports
Abera Bioscience BergenBio Guard Therapeutics Lifecare lundbeck Phase Holographic (amendment) Photocure
Invitation to report presentation and meeting
Bio Vitos Pharma Coloplast ODI Pharma Immunovia Lytix Biopharma Phase Holographic Imaging SciBase
Event participation
Communiqués
Insider trading
This morning's price development
Index: OMXS30 -0,2% Healthcare + 0,07 %
| Winner | Förlorare |
| Active Biotech +123% | PHI -54,3% |
| Gabather +37,5% | Sperm count -17,6% |
| Medim +35,2% | Odinwell -18,4% |
| Tendo +15,7% | Q-Linea -14,7% |
| SpectraCure +13,6% | Magnasense -14% |